高危前列腺癌中GLUT1表达与18F-FDG-PET/CT及临床结局的相关性
该回顾性研究纳入94例活检Gleason评分≥8且根治术前接受18F-FDG-PET/CT的前列腺癌患者,分析GLUT1、GLUT12和HK2表达与SUVmax及临床结局的关系。中位随访4.5年,GLUT1表达与SUVmax相关(r=0.25,p=0.02),高GLUT1表达者SUVmax更高(5.74±1.67 vs 2.68±0.31,p=0.004),且GLUT1表达与淋巴结状态、肿瘤体积、CRPC进展和转移发生相关。
要点
- 高危前列腺癌中GLUT1表达与18F-FDG摄取(SUVmax)呈正相关。
- 高GLUT1表达肿瘤的SUVmax显著高于低表达肿瘤。
- GLUT1表达与淋巴结状态、肿瘤体积、CRPC进展及转移相关。
核心结论
- 前列腺癌肿瘤中GLUT1表达与18F-FDG摄取及不良预后因素相关,提示该转运体参与高危前列腺癌18F-FDG摄取的分子机制。
研究设计与样本
- 回顾性分析2011年7月至2014年7月活检确诊Gleason评分≥8且根治术前接受18F-FDG-PET/CT的前列腺腺癌患者94例。
- 由盲法读片者测量原发灶SUVmax,并由三名病理学家对根治标本免疫组化GLUT1、GLUT12和HK2表达盲法评分。
主要发现
- 中位随访4.5年,56%(n=53)患者出现生化复发,7%(n=7)进展为CRPC,13%(n=12)发生转移,6%(n=6)死亡。
- GLUT1表达与SUVmax相关(r=0.25,p=0.02)。
- 高GLUT1表达肿瘤(n=17)SUVmax为5.74±1.67,高于低GLUT1表达肿瘤(n=71)的2.68±0.31(p=0.004)。
- GLUT1表达水平与SUVmax(p=0.005)、淋巴结状态(p=0.05)、肿瘤体积(p=0.01)、CRPC疾病进展(p=0.02)和转移发生(p=0.04)显著相关。
- GLUT12和HK2表达与SUVmax之间未发现显著差异。
临床怎么用
- 在高危前列腺癌中,GLUT1表达与18F-FDG-PET/CT摄取及不良预后因素相关,提示GLUT1可能作为代谢依赖靶点的研究兴趣。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumour 18F-FDG-uptake is of prognostic value in high-risk and metastatic prostate cancer (PCa). The aim of this study is to investigate the underlying glucose metabolism mechanisms of 18F-FDG-uptake on PET/CT imaging in PCa. METHODS: Retrospective analysis was conducted for 94 patients diagnosed with a Gleason sum ≥8 adenocarcinoma of the prostate at biopsy between July 2011 and July 2014 who underwent 18F-FDG-PET/CT imaging before radical prostatectomy (RP). 18F-FDG-uptake in primary lesion was measured by a blinded reader using maximum standardised uptake value (SUVmax). GLUT1, GLUT12 and HK2 expression were blindly scored after immunohistochemistry on specimens RP by three pathologists. Correlations between GLUT1, GLUT12 and HK2, and SUVmax were assessed using Spearman's rank correlation test. Survival probabilities were based on the Kaplan-Meier method. RESULTS: With a median follow-up of 4.5 years, 56% (n = 53) of patients had biochemical recurrence (BCR), 7% (n = 7) progressed to castration-resistant prostate cancer (CRPC) disease, 13% (n = 12) developed metastasis and 6% (n = 6) died. Correlation was found between GLUT1 expression and SUVmax level (r = 0.25, p = 0.02). In addition, SUVmax was significantly higher in tumours with high GLUT1 expression (n = 17, 5.74 ± 1.67) than tumours with low GLUT1 expression (n = 71, 2.68 ± 0.31, p = 0.004). Moreover, a significant association was found between GLUT1 expression levels and SUVmax level (p = 0.005), lymph node status (p = 0.05), volume of cancer (p = 0.01), CRPC disease progression (p = 0.02) and metastasis development (p = 0.04). No significant difference between GLUT12 and HEX2 expression and SUVmax have been found. CONCLUSIONS: GLUT1 expression in PCa tumours correlates with 18F-FDG-uptake and poor prognostic factors. These results suggest that this transporter is involved in the molecular mechanism of 18F-FDG-uptake in high-risk PCa and raise interest in targeting metabolic dependencies of PCa cells as a selective anticancer strategy.
引用
- Meziou S, Ringuette Goulet C, Hovington H, et al. GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome. Prostate Cancer Prostatic Dis. 2020. PMID: 31932660. doi:10.1038/s41391-020-0202-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。